WebApr 6, 2024 · Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also … WebApr 6, 2024 · Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined …

Gemini Therapeutics Announces GEM103 Meets All Endpoints in ... - Eyewire+

WebGemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their … WebDec 29, 2024 · Gemini Therapeutics, Inc. (GMTX) has announced a 1-for-10 reverse stock split, and a name, symbol, and CUSIP change, in conjunction with a reverse merger with Disc Medicine, Inc. As a result, each GMTX Common Share will be converted into the right to receive 0.10 (New) Disc Medicine, Inc. (IRON) Common myle hold me lyrics

GMTX Gemini Therapeutics Inc - Stocktwits

WebGemini Therapeutics Inc market cap is $427.64M. What is the 52-week high for Gemini Therapeutics Inc? 52 week high is the highest price of a stock in the past 52 weeks, or one year. Gemini Therapeutics Inc 52 week high is $26.43 as of April 10, 2024. WebApr 11, 2024 · macular degeneration (dry AMD) while at Gemini Therapeutics. As Senior Director and Clinical Development Lead for Ophthalmology at Editas Medicine, Dr. Rashid helped lead clinical development for its CRISPR/Cas9 gene editing technology for patients with Leber congenital amaurosis type 10 (LCA10) – a rare genetic disease that causes … WebApr 11, 2024 · BOSTON, April 11, 2024 /PRNewswire/ --Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today three new appointments to its growing ... my lehre/pts